

## CHRONIC OBSTRUCTIVE PULMONARY DISEASE

# Measurement of physiological recovery from exacerbation of chronic obstructive pulmonary disease using within-breath forced oscillometry

Martin K Johnson, Malcolm Birch, Roger Carter, John Kinsella, Robin D Stevenson

*Thorax* 2007;62:299–306. doi: 10.1136/thx.2006.061044

**Background:** Within-breath reactance from forced oscillometry estimates resistance via its inspiratory component ( $X_{rs,insp}$ ) and flow limitation via its expiratory component ( $X_{rs,exp}$ ).

**Aim:** To assess whether reactance can detect recovery from an exacerbation of chronic obstructive pulmonary disease (COPD).

**Method:** 39 subjects with a COPD exacerbation were assessed on three occasions over 6 weeks using post-bronchodilator forced oscillometry, arterial blood gases, spirometry including inspiratory capacity, symptoms and health-related quality of life (HRQOL).

**Results:** Significant improvements were seen in all spirometric variables except the ratio of forced expiratory volume in 1 s (FEV<sub>1</sub>) to vital capacity, ranging in mean (SEM) size from 11.0 (2.2)% predicted for peak expiratory flow to 12.1 (2.3)% predicted for vital capacity at 6 weeks. There was an associated increase in arterial partial pressure of oxygen (PaO<sub>2</sub>). There were significant mean (SEM) increases in both  $X_{rs,insp}$  and  $X_{rs,exp}$  (27.4 (6.7)% and 37.1 (10.0)%, respectively) but no change in oscillometry resistance ( $R_{rs}$ ) values. Symptom scales and HRQOL scores improved. For most variables, the largest improvement occurred within the first week with spirometry having the best signal-to-noise ratio. Changes in symptoms and HRQOL correlated best with changes in FEV<sub>1</sub>, PaO<sub>2</sub> and  $X_{rs,insp}$ .

**Conclusions:** The physiological changes seen following an exacerbation of COPD comprised both an improvement in operating lung volumes and a reduction in airway resistance. Given the ease with which forced oscillometry can be performed in these subjects, measurements of  $X_{rs,insp}$  and  $X_{rs,exp}$  could be useful for tracking recovery.

See end of article for authors' affiliations

Correspondence to:  
Dr M K Johnson, Department of Respiratory Medicine, Gartnavel General Hospital, 1053 Great Western Road, Glasgow G12 0YN, UK; johnson77@btinternet.com

Received 13 March 2006  
Accepted 10 October 2006

Changes in lung function, symptoms and health-related quality of life (HRQOL) during exacerbations of chronic obstructive pulmonary disease (COPD) have previously been evaluated. Lung function has been assessed by peak expiratory flow (PEF)<sup>1,2</sup> and spirometry.<sup>1,3,4</sup> The largest rates of change occurred in the first few days of the exacerbation with greater increases in FEV<sub>1</sub> over the first 2 days being predictive of superior clinical outcome.<sup>5</sup> Recovery was sometimes slow and incomplete with only 75% having regained their original PEF by 35 days after the exacerbation and 7.1% not returning to baseline lung function at 3 months.<sup>1</sup> Changes in symptoms have been determined using patient diaries,<sup>1,6</sup> with the onset of symptoms occurring before changes in lung function.<sup>1</sup> Improvement in disease-specific HRQOL following a transient fall due to an exacerbation has been shown using the St George's Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ).<sup>2,7,8</sup> Improvement in HRQOL following an exacerbation has been shown to be curtailed if a further exacerbation occurs during recovery.<sup>9</sup>

### Physiological measurements


Forced oscillometry is a method of measuring the resistive properties of the respiratory system, which can delineate within-breath changes with sub-second resolution.<sup>10</sup> Its output is commonly expressed as two variables, resistance ( $R_{rs}$ ) and reactance ( $X_{rs}$ ), which represent the spectral relationship between pressure and flow of a low-amplitude sinusoidal forcing signal entrained in the air that the subject breathes.  $R_{rs}$  is derived from the in-phase relationship and is thought to be a direct estimate of resistance.  $X_{rs}$  is calculated from the out-of-phase relationship. In normal subjects, it is thought to

reflect elastic and inertive properties but, in subjects with airway obstruction, inspiratory values of  $X_{rs}$  have a stronger linear relationship with transpulmonary resistance than do the equivalent  $R_{rs}$  values.<sup>11</sup> In addition, expiratory values of  $X_{rs}$  have been used to establish the presence of expiratory flow limitation.<sup>12,13</sup>

Forced oscillometry may be particularly appropriate for the objective physiological assessment of patients with an exacerbation of COPD. It is a passive manoeuvre that requires only tidal breathing, and is easily performed by breathless subjects. Further, within-breath measurements of  $X_{rs}$  could be used to estimate simultaneously both airway resistance and degree of expiratory flow limitation. To date, only one study has reported forced oscillometry data during an exacerbation of COPD.<sup>14</sup> This confirmed the expectation that  $R_{rs}$  would not change but that  $X_{rs}$  would rise significantly towards more normal values as the exacerbation resolved. Within-breath  $X_{rs}$  data during an exacerbation of COPD have not been reported.

The aim of this study was to assess the ability of within-breath forced oscillometry to detect longitudinal physiological changes during an exacerbation of COPD in comparison with spirometry, gas exchange, symptoms and HRQOL.

**Abbreviations:** ADLs, activities of daily living; COPD, chronic obstructive pulmonary disease; FEV<sub>1</sub>, forced expiratory volume in 1 s; HRQOL, health-related quality of life; LCADL, London Chest Activities of Daily Living; PaO<sub>2</sub>, arterial partial pressure of oxygen; PEF, peak expiratory flow; OCD, oxygen cost diagram;  $R_{rs}$ , resistance of the respiratory system; SGRQ, St George's Respiratory Questionnaire; TDI, Transitional Dyspnoea Index; VAS, visual analogue scale;  $X_{rs}$ , reactance of the respiratory system;  $Z_{rs}$ , impedance of the respiratory system



**Figure 1** Study design showing order of tests. HRQOL, health-related quality of life.

## METHODS

### Subjects

Patients with a clinical diagnosis of COPD admitted to the medical receiving ward or referred to the Acute Respiratory Assessment Service at Glasgow Royal Infirmary (GRI) were approached to take part in the study. They were within 48 h of the point of presentation when first assessed, age >40 years, smoking history >20 pack-years and had baseline spirometry which satisfied the British Thoracic Society definition of COPD (ie,  $FEV_1 < 80\%$  predicted and  $FEV_1$  to forced vital capacity ratio <70%).<sup>15</sup> They had recognised features of an exacerbation, the criteria used here being increased breathlessness for at least 24 h with at least two criteria of increased cough frequency or severity, increased sputum volume or purulence or increased wheeze.<sup>16</sup> The only exclusion criterion was decompensated respiratory failure.

To detect a change in  $R_{rs}$  of approximately  $0.05 \text{ kPa} \cdot \text{s/l}$  with 80% power and a significance level of 0.05, the sample size required was 35 assuming a SD for the change of approximately  $0.15 \text{ kPa} \cdot \text{s/l}$ . Given that some attrition was expected because of the frail condition of the study subjects, it was decided to aim for 50 patients in total. Ethical approval for this study was obtained from the GRI Local Research and Ethics Committee (Glasgow, UK) and written informed consent was given by each subject.

### Study design

This was a longitudinal observational study (summarised in fig 1). At the start of each visit the subject received 5 mg nebulised salbutamol delivered over 10–15 min in a 2.5 ml volume using a jet nebuliser (Micro-Neb Nebuliser, Lifecare Hospital Supplies, Market Harborough, UK) driven by an air flow of 8 l/min (Aquilon Nebuliser System, AFP Medical, Rugby, UK) through a facemask (Duo Mask Adult, Lifecare Hospital Supplies). Measurements were performed 20 min after the nebulised salbutamol had been given. Visit 2 was scheduled to occur at approximately 1 week after visit 1, and visit 3 at 6 weeks. If the patient had a relapse between visits 2 and 3 which required hospital admission or further treatment by the hospital at home team, visit 3 was postponed until the patient was in a stable condition at home and on normal treatment. One operator (MKJ) performed all tests and was blinded to the results of earlier tests.


### Physiological measurement

Spirometry was performed using a laptop-based spirometer (KoKo Spirometer, Ferraris Respiratory, Louisville, Kentucky, USA). The variables measured were slow vital capacity,  $FEV_1$ ,  $FEV_1$  to vital capacity ratio, inspiratory capacity and PEF. Quality control and procedures of testing followed the guidelines of the European Respiratory Society endorsed by the British Thoracic Society and the Association of Respiratory Technology and Physiology.<sup>17, 18</sup> Results of at least three satisfactory manoeuvres were obtained and the reported values were the highest values for  $FEV_1$ , vital capacity and PEF and

the mean result for  $FEV_1$ /vital capacity. Inspiratory capacity was measured during a slow expiratory vital capacity manoeuvre where a period of tidal breathing was followed by inspiration to total lung capacity to record inspiratory capacity and then a full expiration to residual volume to give vital capacity. Performance of this procedure was checked visually and repeated until two inspiratory capacity values were within 10% of each other. The average of these two values was used. Predicted normal values were calculated using the European Community for Steel and Coal equations.<sup>17</sup> Predicted inspiratory capacity was calculated by subtracting predicted functional residual capacity from predicted total lung capacity.

Sampling of earlobe arterialised capillary blood was performed to obtain values for arterial partial pressure of oxygen ( $PaO_2$ ) and carbon dioxide ( $PaCO_2$ ).<sup>19</sup> A nicotine vasodilator cream (Transvasin, SSL International, Knutsford, UK) was applied to the earlobe 20 min before blood sampling. The earlobe was then punctured using a 21 G needle, blood was collected into a heparinised 140  $\mu\text{l}$  capillary tube (Multicap, Bayer Diagnostics, Sudbury, UK) and analysed immediately on an arterial blood gas analyser (Chiron Diagnostics Rapidlab 865, Halstead, UK).

The method for forced oscillometry has been described in detail elsewhere<sup>11</sup> and followed the recently published European Respiratory Society recommendations.<sup>10</sup> While the subject performed tidal breathing through a mouthpiece with nose occluded and cheeks supported, the oscillometer performed within-breath measurements of the impedance of the respiratory system ( $Z_{rs}$ ) using a sinusoidal excitation signal of 5 Hz frequency generated by a loudspeaker. A bias flow of 0.25 l/s of air was fed into the breathing circuit in order to minimise rebreathing. Calculation of  $Z_{rs}$  was performed by software. The breathing and forcing waveforms were separated using a moving average filter<sup>20</sup> and  $Z_{rs}$  was calculated from the forcing waveforms using the method based upon power spectra,<sup>21</sup> further adapted for within-breath analysis.<sup>20</sup> This was separated into  $R_{rs}$  and  $X_{rs}$  and calculated as a function of time at each digitisation point (sampling frequency of 200 Hz) using the 0.2 s interval of flow and pressure centred on that point. These within-breath values were low-pass filtered to remove biological noise using a Butterworth eight-pole filter with a cut-off frequency of 2 Hz. The  $R_{rs}$  and  $X_{rs}$  values were averaged over the inspiratory ( $R_{rs,insp}$ ,  $X_{rs,insp}$ ) and expiratory ( $R_{rs,exp}$ ,  $X_{rs,exp}$ ) phases of each breath to give separate values for the two phases of the respiratory cycle. The studies by Dellaca *et al*<sup>12, 13</sup> showed that, in subjects with COPD, the difference between mean values of inspiratory and expiratory reactance (ie,  $\Delta X_{rs}$  which equals  $X_{rs,insp} - X_{rs,exp}$ ) could detect expiratory flow limitation proven by oesophageal manometry with high sensitivity and specificity. In the later study,<sup>13</sup>  $\Delta X_{rs} > 0.275 \text{ kPa} \cdot \text{s/l}$  had a sensitivity of 95% and specificity of 98% for detecting



**Figure 2** Flowchart showing recruitment of subjects. COPD, chronic obstructive pulmonary disease.

**Table 1** Baseline values from visit 1

	Baseline values
Number (n, male)	39 (16)
Age (years)	63.1 (6.9)
Number with BMI <25:25–30:>30	19:13:7
Smoking history	
Ex or current smokers:lifelong non-smokers	39:0
Pack-years	40 (10–100)*
Time interval (days)	
Admission–visit 1	2 (0–3)*
Visit 1–visit 2	7 (3–15)*
Visit 1–visit 3	42 (35–102)*
Spirometry	
VC	
Litres	2.45 (0.90)
% predicted	88 (25)
FEV <sub>1</sub>	
Litres	0.96 (0.42)
% predicted	43 (16)
FEV <sub>1</sub> /VC (%)	40 (10)
PEF	
l/s	2.75 (1.11)
% predicted	43 (16)
IC	
Litres	1.70 (0.65)
% predicted	77 (28)
Capillary earlobe blood gases	
PaO <sub>2</sub> (kPa)	8.07 (1.35)
PaCO <sub>2</sub> (kPa)	4.74 (0.77)
Breathing pattern	
Respiratory rate (/min)	19.3 (5.6)
Tidal volume (l)	0.737 (0.249)
Oscillometry	
R <sub>rs</sub> (kPa. s/l)	0.605 (0.194)
X <sub>rs</sub> (kPa. s/l)	–0.594 (0.269)
R <sub>rs,insp</sub> (kPa. s/l)	0.517 (0.152)
X <sub>rs,insp</sub> (kPa. s/l)	–0.298 (0.117)
R <sub>rs,exp</sub> (kPa. s/l)	0.658 (0.231)
X <sub>rs,exp</sub> (kPa. s/l)	–0.776 (0.389)
%FL (%)	68 (35)
Symptom score	
VAS	
Sleep	–37.6 (42.7)
Wheeze	–39.4 (36.0)
Mobility	–65.8 (34.5)
Paggiaro	9.18 (2.73)
Dyspnoea	
VAS	39.7 (25.9)
BDI	3.79 (2.58)
TDI	–5.41 (1.55)
OCD	0.280 (0.088)
Borg	3.62 (1.54)
Impairment of activities of daily living (LCADL)	54.1 (5.8)
Health-related quality of life (SGRQ)	
Symptoms	83.1 (13.9)
Activities	87.9 (11.9)
Impacts	62.8 (16.2)
Total	73.8 (12.5)

ADLs, activities of daily living; BDI, Baseline Dyspnoea Index; BMI, body mass index; FEV<sub>1</sub>, forced expiratory volume in 1 s; %FL, percentage flow limitation; IC, inspiratory capacity; LCADL, London Chest Activities of Daily Living; OCD, oxygen cost diagram; PaCO<sub>2</sub>, arterial partial pressure of carbon dioxide; PEF, peak expiratory flow; PaO<sub>2</sub>, arterial partial pressure of oxygen; R<sub>rs</sub>, resistance of the respiratory system; SGRQ, St George's Respiratory Questionnaire; TDI, Transitional Dyspnoea Index; VAS, visual analogue scale; VC, vital capacity; X<sub>rs</sub>, reactance of the respiratory system. All data are mean (SD) unless otherwise indicated.

\*Median (range).

breaths as flow limited. Percentage flow limitation, which represents the proportion of breaths for which  $\Delta X_{rs}$  indicated the flow limitation, was calculated for the subjects in this study. For all oscillometry variables, values from two recordings of 1 min duration were averaged.

### Symptom scales and HRQOL questionnaires

Symptoms were assessed using visual analogue scales (VAS) for sleep, wheeze and mobility derived from Davies<sup>16</sup> and a numerical scale used by Paggiaro.<sup>22</sup> Dyspnoea was measured by four scales: VAS,<sup>16</sup> modified Borg score,<sup>23</sup> oxygen cost diagram (OCD)<sup>24</sup> and the Baseline and Transitional Dyspnoea Indices (BDI/TDI).<sup>25</sup> Activities of daily living (ADLs) were assessed using the London Chest Activities of Daily Living Questionnaire (LCADL).<sup>26</sup> HRQOL was assessed using the St George's Respiratory Questionnaire (SGRQ).<sup>27</sup>

### Statistical analysis

Baseline results were summarised either as mean (SD) or median (range) and changes as mean (SEM). The changes in each test parameter were analysed between visit 2 and visit 1, visit 3 and visit 1, and visit 3 and visit 2 using the Student's paired *t* test. To compare the relative utility of each variable, a sensitivity index<sup>28</sup> was calculated from the size of the change divided by the coefficient of variation.<sup>29</sup> To assess the relationship between changes in physiological variables and symptoms or HRQOL, Pearson's correlation coefficients were calculated for changes in the key variables between visit 1 and visit 3. The level of statistical significance was taken as 0.05 throughout. All statistics were performed with Statview V.5.0.1.

## RESULTS

### Subjects


Figure 2 summarises the recruitment of subjects into this study. Eighty six subjects with COPD were approached to take part. Of the 50 subjects who consented, five were excluded (three by spirometry showing absence of airways obstruction and two were non-smokers with bronchiectasis). A further six failed to attend after the first visit, leaving evaluable data on 39 subjects. The subjects successfully completed all the study protocols at the visits they attended and all had airways obstruction at their final visit after recovery from the exacerbation.

### Baseline results

The data in table 1 summarise the physiological status of the subjects at visit 1. Mean spirometry values showed moderate airway obstruction with a reduced inspiratory capacity similar to values elsewhere.<sup>2</sup> Approximately half the subjects were in respiratory failure (mainly type 1). The oscillometry results showed increased magnitude of R<sub>rs</sub> and X<sub>rs</sub> compared with normal values.<sup>10</sup> Expiratory flow limitation (indicated by  $\Delta X_{rs}$ ) was present to some degree in 37 of the 39 subjects at visit 1. If expiratory flow limitation was present, not all breaths were necessarily affected, the proportion ranging from 0% to 100% with a mean of 68% (table 1). The number showing flow limitation dropped on subsequent visits to 30 of 37 subjects at visit 2 and 24 of 36 subjects at visit 3. The patients were more symptomatic than normal, reflected by their VAS scores for sleep, wheeze and mobility and by their values on the TDI scale. ADLs were severely impaired and HRQOL was poor, with SGRQ values higher than those quoted by Spencer and Jones.<sup>7</sup>

### Change during exacerbation

Figure 3 shows within-breath X<sub>rs</sub> and R<sub>rs</sub> results for three representative subjects from the three study visits. Qualitatively, it can be seen that the three subjects show a larger proportional change in X<sub>rs</sub> than R<sub>rs</sub>. Table 2 shows the




**Figure 3** Within-breath resistance ( $R_{rs}$ ) and reactance ( $X_{rs}$ ) values from three subjects (A, B and C) showing the typical patterns of change between visits 1 and 3. The three subjects show a larger proportional change in  $X_{rs}$  than  $R_{rs}$ . Subject A experienced most improvement between study visits 2 and 3 whereas subject B changed most between visits 1 and 2. Subject C also showed improvement in both  $X_{rs,insp}$  and  $X_{rs,exp}$  but the continued expiratory fall in  $X_{rs,exp}$  suggested persistent flow limitation during tidal breathing throughout the study.

changes in physiological variables during the exacerbation. Percentage change values were derived in different ways for the spirometry and oscillometry variables. As lung volumes and flows were typically reduced and reliable predicted values available, these were given as percentage change relative to the predicted values. As oscillometry values were higher than normal during the exacerbation and predicted values less well known, the denominator for percentage change was the average of the values at the relevant visit. Figure 4 summarises these results. The changes between visits 2 and 3 are not shown in detail as they were smaller and generally not significant (with the exception of  $FEV_1$ , PEF,  $X_{rs,insp}$ , Paggiaro Symptom Score, TDI, Dyspnoea (VAS) and LCADL, which were marginally significant). Figure 5 illustrates this time course of change.

To obtain a measure of the “signal-to-noise” content or sensitivity index of the physiological measurements,<sup>28</sup> the changes between visits 1 and 3 are shown in table 3 divided by the reproducibility or coefficient of variation of the measurement.<sup>29</sup>  $FEV_1$ , vital capacity and inspiratory capacity were the more reliable measurements followed by the  $X_{rs}$  variables.

### Correlation between physiological variables and symptoms

Pearson’s correlation coefficients were calculated between changes in physiological variables and changes in symptoms or HRQOL, and are shown in supplementary table E1 (available at <http://thorax.bmj.com/supplemental>). The strongest correlation was seen between changes in  $PaO_2$  and OCD scores ( $r = 0.594$ ;  $p = 0.0001$ ). Of the spirometric variables, changes in  $FEV_1$  showed the strongest associations with changes in symptoms, having significant correlations with changes in OCD ( $r = 0.500$ ;  $p = 0.002$ ), TDI ( $r = 0.372$ ;  $p = 0.02$ ) and LCADL score ( $r = 0.499$ ;  $p = 0.002$ ). By contrast, changes in inspiratory capacity were only associated with changes in mobility ( $r = 0.329$ ;  $p = 0.05$ ). Changes in  $X_{rs,insp}$  were widely associated with changes in symptoms, showing positive correlations with changes in OCD ( $r = 0.430$ ;  $p = 0.01$ ), TDI ( $r = 0.458$ ;  $p = 0.009$ ), LCADL ( $r = 0.408$ ;  $p = 0.01$ ) and mobility ( $r = 0.493$ ;  $p = 0.003$ ). Changes in  $X_{rs,exp}$  showed fewer significant correlations. Both changes in  $X_{rs,insp}$  and  $X_{rs,exp}$  showed significant correlations with change in total SGRQ score ( $r = 0.442$ ,  $p = 0.003$  and  $r = 0.428$ ,  $p = 0.009$ ).



**Figure 4** Comparison of the magnitude of the mean percentage changes in spirometry and oscillometry parameters between visits 1 and 3. Spirometry values are given as change in percentage predicted. Percentage changes in oscillometry parameters were calculated by averaging the results from the first and last visits and using this as the denominator. Error bars show SEM. \* $p < 0.005$ , † $p < 0.001$ , NS, not significant. FEV<sub>1</sub>, forced expiratory volume in 1 s; %FL, percentage flow limitation; IC, inspiratory capacity; PEF, peak expiratory flow; R<sub>rs</sub>, resistance of the respiratory system; VC, vital capacity; X<sub>rs</sub>, reactance of the respiratory system.

## DISCUSSION

This study has shown that improvement after an exacerbation of COPD can be detected either objectively by physiological measurements such as spirometry, oscillometry or gas exchange or subjectively by the simpler stratagem of following symptom scores or HRQOL (table 2 and fig 4). The majority of the improvement in all variables occurred within the first week of monitoring (table 2, fig 5).


In the study subjects there was a uniformly significant improvement in symptoms, ADLs and improvement in SGRQ (with the exception of the symptoms score) confirming subjective recovery from the exacerbation. All the spirometric variables (ie, FEV<sub>1</sub>, PEF, vital capacity and inspiratory capacity) increased significantly with the exception of FEV<sub>1</sub>/vital capacity, which is in line with findings elsewhere.<sup>1-4</sup> One difference found here was that the size of the change was very consistent in terms of percentage predicted, ranging from 11% for PEF to 12.1% for vital capacity. This diverges slightly from the results in the recent similar study by Stevenson *et al* where the absolute value of inspiratory capacity was lower throughout and the change in inspiratory capacity was found to be larger (19% predicted).<sup>14</sup> Three factors which could account for these differences are the timing of the measurements, the baseline characteristics of the study populations and the technique used to measure inspiratory capacity. First, the patients in this study had their initial measurements performed on average a day later than those in studied by Stevenson *et al*, by which time they had already documented an increase in inspiratory capacity approaching 0.1 litre. Second, the subjects in Stevenson's study at baseline had lower BMI and higher PaO<sub>2</sub> values than those in this study. Being underweight and relatively well oxygenated are two characteristics of the group of patients formerly called "pink puffers" whose other key characteristic is marked hyperinflation and, hence, a relatively reduced inspiratory capacity. Third, inspiratory capacity was measured in this study during an expiratory vital capacity manoeuvre, whereas an inspiratory approach was used by Stevenson *et al*.

The subjects in this study showed a sizeable and significant increase in both X<sub>rs,insp</sub> and X<sub>rs,exp</sub> (27.4% and 37.1%, respectively). As explained earlier, this can be interpreted physically as a decrease in both transpulmonary resistance and expiratory flow limitation, respectively, during the study period. By comparison, there was no change in R<sub>rs,insp</sub> and R<sub>rs,exp</sub> (3.91% and 1.25%, respectively). The study by Stevenson *et al*<sup>14</sup>

is the only previous report of longitudinal changes of forced oscillometry variables during an exacerbation of COPD, and this showed a strikingly similar pattern of change to that seen here. They interpreted the lack of change in R<sub>rs</sub> as implying that resistance does not improve during an exacerbation of COPD,<sup>14</sup> but this inference can be contested. First, in subjects with COPD, airway obstruction is present both during the exacerbation and after recovery. In this situation, the relationship between transpulmonary resistance and R<sub>rs</sub> is weakened by the upper airway wall shunt,<sup>11</sup> and changes in the former may not be reflected in the measured R<sub>rs</sub> value. Second, a fall in resistance during recovery from an exacerbation is suggested by the significant rise in FEV<sub>1</sub> seen in this study. According to several models of flow limitation, maximal expiratory flow and, hence, FEV<sub>1</sub> is dictated by the balance between thoracic elastic recoil and resistive pressure drop.<sup>30</sup> As recovery progressed in this study, the degree of hyperinflation in the subjects reduced and the magnitude of elastic recoil must have fallen. To produce an increase in FEV<sub>1</sub>, there must have been a simultaneous and slightly greater fall in resistance.

To compare the relative ability of spirometry and oscillometry to detect improvement during an exacerbation of COPD, the sensitivity index of each variable was calculated by dividing the change in the variable by its coefficient of variation (table 3). This effectively estimated the variable's signal-to-noise ratio. It can be seen that spirometry was the superior measurement in this analysis. The coefficient of variation of the X<sub>rs</sub> results could be improved by increasing the amplitude of the 5 Hz forcing signal, which would improve signal-to-noise ratio, or by increasing the number of data points averaged in the calculation of one X<sub>rs</sub> value (by either prolonging the duration of data collection or increasing the number of times the measurement is repeated).

To assess the ability of changes in physiological variables to predict changes in symptoms or HRQOL, the correlation coefficients between changes in these variables from visit 1 to visit 3 were calculated (shown in the supplement available at <http://thorax.bmj.com/supplemental>). The broadest association with symptomatic improvement was found for changes in FEV<sub>1</sub>, PaO<sub>2</sub> and X<sub>rs,insp</sub>. Only changes in the oscillometry variables (X<sub>rs,insp</sub> and X<sub>rs,exp</sub>) were associated with changes in HRQOL. Conversely, the symptom scales most broadly associated with physiological improvement appeared to be the TDI score and the VAS for mobility. Changes in Borg score were not correlated with physiological improvement and changes in PEF



**Figure 5** Time course of recovery of physiological variables. (A) Volumes and flows; (B)  $X_{rs}$ ; (C) %FL. Values are mean change relative to visit 1. Error bars show SEM. FEV<sub>1</sub>, forced expiratory volume in 1 s; %FL, percentage flow limitation; IC, inspiratory capacity; PEF, peak expiratory flow; VC, vital capacity;  $X_{rs}$ , reactance of respiratory system.

were not associated with symptom or HRQOL changes. The strength of all significant associations was modest at best. If the conservative Bonferroni correction was applied to compensate for the multiple statistical comparisons made, then only the association between changes in PaO<sub>2</sub> and changes in OCD score remained positive.

A surprising aspect of the correlation analysis was the relatively weak association of change in inspiratory capacity with symptomatic improvement. It has recently been shown that change in resting inspiratory capacity post-bronchodilator is the strongest predictor of subsequent improvement in exercise capacity.<sup>31</sup> Also, Stevenson *et al*<sup>14</sup> found that patients reporting less breathlessness at the time of discharge were those in whom inspiratory capacity improved most during

**Table 2** Change in variables between visits for all patients

	Visit 2–visit 1 (n = 37)	Visit 3–visit 1 (n = 36)
<b>Spirometry</b>		
VC		
Litre	0.297 (0.061) <sup>§</sup>	0.354 (0.071) <sup>§</sup>
% predicted	10.3 (1.8) <sup>§</sup>	12.1 (2.3) <sup>§</sup>
FEV <sub>1</sub>		
Litre	0.153 (0.046) <sup>‡</sup>	0.274 (0.064) <sup>§</sup>
% predicted	6.4 (1.7) <sup>‡</sup>	11.4 (2.3) <sup>§</sup>
FEV <sub>1</sub> /VC (%)	0.2 (1.1)	3.18 (1.47) <sup>‡</sup>
PEF		
l/s	0.455 (0.140) <sup>‡</sup>	0.696 (0.142) <sup>§</sup>
% predicted	6.8 (2.2) <sup>‡</sup>	11.0 (2.2) <sup>§</sup>
IC		
Litre	0.241 (0.054) <sup>§</sup>	0.295 (0.056) <sup>§</sup>
% predicted	9.87 (1.98) <sup>§</sup>	11.9 (2.3) <sup>§</sup>
<b>Capillary earlobe blood gases</b>		
PaO <sub>2</sub> (kPa)	0.85 (0.18) <sup>§</sup>	1.18 (0.21) <sup>§</sup>
PaCO <sub>2</sub> (kPa)	0.06 (0.13)	0.02 (0.14)
<b>Breathing pattern</b>		
Respiratory rate (/min)	-1.37 (0.65) <sup>‡</sup>	-1.57 (0.64) <sup>‡</sup>
Tidal volume (l)	-0.002 (0.029)	0.008 (0.183)
<b>Oscillometry</b>		
R <sub>rs</sub>		
KPa·s/l	-0.025 (0.02)	-0.009 (0.024)
%	-3.60 (3.47)	-0.95 (3.90)
X <sub>rs</sub>		
KPa·s/l	0.132 (0.034) <sup>§</sup>	0.143 (0.039) <sup>‡</sup>
%	27.9 (7.0) <sup>§</sup>	35.2 (8.9) <sup>§</sup>
R <sub>rs, insp.</sub>		
KPa·s/l	-0.025 (0.015)	-0.024 (0.019)
%	-4.97 (3.25)	-3.90 (3.9)
X <sub>rs, insp.</sub>		
KPa·s/l	0.032 (0.011) <sup>‡</sup>	0.073 (0.017) <sup>§</sup>
%	13.0 (4.5) <sup>‡</sup>	27.4 (6.7) <sup>§</sup>
R <sub>rs, exp.</sub>		
KPa·s/l	-0.02 (0.027)	0.006 (0.03)
%	-2.57 (4.09)	1.25 (4.22)
X <sub>rs, exp.</sub>		
KPa·s/l	0.19 (0.05) <sup>§</sup>	0.18 (0.05) <sup>‡</sup>
%	31.5 (7.8) <sup>§</sup>	37.1 (10.0) <sup>‡</sup>
%FL (%)	-19.2 (6.1) <sup>‡</sup>	-19.5 (7) <sup>‡</sup>
<b>Symptom score</b>		
VAS		
Sleep	30.5 (8.1) <sup>‡</sup>	23.5 (9.3) <sup>‡</sup>
Wheeze	17.7 (6.5) <sup>‡</sup>	22.6 (8.4) <sup>‡</sup>
Mobility	31.8 (6.5) <sup>§</sup>	37.1 (7.6) <sup>§</sup>
Paggiaro	-1.70 (0.54) <sup>‡</sup>	-3.14 (0.62) <sup>§</sup>
<b>Dyspnoea</b>		
VAS	16.9 (4.3) <sup>§</sup>	27.0 (5.7) <sup>§</sup>
TDI	1.92 (0.33) <sup>§</sup>	3.39 (0.405) <sup>§</sup>
OCD	0.068 (0.018) <sup>‡</sup>	0.101 (0.027) <sup>‡</sup>
Borg	-0.973 (0.205) <sup>§</sup>	-1.15 (0.281) <sup>‡</sup>
<b>Impairment of activities of daily living (LCADL)</b>		
SGRQ		
Symptoms		0.12 (2.41)
Activities		-4.76 (2.26) <sup>‡</sup>
Impacts		-9.88 (2.92) <sup>‡</sup>
Total		-6.67 (1.96) <sup>‡</sup>

ADLs, activities of daily living; FEV<sub>1</sub>, forced expiratory volume in 1 s; %FL, percentage flow limitation; IC, inspiratory capacity; LCADL, London Chest Activities of Daily Living; OCD, oxygen cost diagram; PEF, peak expiratory flow; PaCO<sub>2</sub>, arterial partial pressure of carbon dioxide; PaO<sub>2</sub>, arterial partial pressure of oxygen; R<sub>rs</sub>, resistance of the respiratory system; SGRQ, St George's Respiratory Questionnaire; TDI, Transitional Dyspnoea Index; VAS, visual analogue scale; VC, vital capacity; X<sub>rs</sub>, reactance of the respiratory system.

All data are mean (SEM) unless otherwise indicated.

The statistical significance of paired changes was assessed using the Student's paired t test. The statistical significance of percentage changes was assessed using the equivalent one sample test, with the null hypothesis being a mean change of zero.

\*p<0.1, †p<0.05, ‡p<0.005, §p<0.001.

**Table 3** Sensitivity index of spirometry and oscillometry measurements

	Change (visit 3–visit 1)	Coefficient of variation (%)	Sensitivity index
Spirometry (% change)			
VC	15.5	7.2	2.15
FEV <sub>1</sub>	24.8	9.6	2.58
IC	16.7	8.8	1.90
Oscillometry (% change)			
R <sub>rs</sub>	−0.95	12.2	0.08
X <sub>rs</sub>	35.2	24.1	1.46
R <sub>rs,insp</sub>	−3.9	14.0	0.28
X <sub>rs,insp</sub>	27.4	17.6	1.56
R <sub>rs,exp</sub>	1.25	13.2	0.09
X <sub>rs,exp</sub>	37.1	28.6	1.30
%FL	−19.5	13.3	1.47

FEV<sub>1</sub>, forced expiratory volume in 1 s; %FL, percentage flow limitation; IC, inspiratory capacity; R<sub>rs</sub>, resistance of the respiratory system; VC, vital capacity; X<sub>rs</sub>, reactance of the respiratory system.

This analysis uses percentage change rather than percentage predicted values for spirometry in order to be comparable with the coefficient of variation.

recovery. One factor contributing to this difference was that the patients in this study showed a slightly different pattern of physiological abnormality at baseline and change during recovery. The patients here showed more of an obstructive picture (mean baseline FEV<sub>1</sub> 0.96 l (43% predicted) compared with 1.03 l (47% predicted)<sup>14</sup>; mean change in FEV<sub>1</sub> 0.274 l (11.4% predicted) compared with 0.20 l<sup>14</sup>) and less hyperinflation (mean baseline inspiratory capacity 1.70 l (77% predicted) compared with 1.37 l (62% predicted)<sup>14</sup>; change in inspiratory capacity 0.295 l (11.9% predicted) compared with 0.42 l (19% predicted)<sup>14</sup>). When combined with the inferior reproducibility (in absolute terms) of inspiratory capacity measurements, the biological noise in the measurements may have masked the association between change in inspiratory capacity and change in symptoms or HRQOL in this study.

Several difficulties were encountered in performing this study. First, unless pre-exacerbation data are available, there are no precise objective criteria for establishing when a patient has reached a stable state post-exacerbation. This was defined pragmatically here as a time point at least 6 weeks after visit 1 with the patient at home in what they deemed a stable condition and on normal drugs. Second, it was difficult to achieve complete follow-up with the type of subjects in this study due to chronic, severe symptoms and the tendency to relapse. For clinical reasons there was some variability in the exact time point at which the patients were assessed, but the principle of assessing them at the beginning, early in recovery and then when largely back to stable state was achieved with reasonable success.

In conclusion, the physiological changes seen during recovery from an exacerbation of COPD comprised both an improvement in operating lung volumes (shown by inspiratory capacity) and a reduction in airway obstruction (assessed by FEV<sub>1</sub> and X<sub>rs</sub>). Forced oscillometry is potentially an attractive and simple test to perform in patients with breathlessness because it is a passive manoeuvre requiring only tidal breathing. Spirometry does have superior signal-to-noise behaviour but, compared with oscillometry, it is a maximal test that can be unpleasant to perform and leads to increased symptoms after the procedure. Changes in X<sub>rs,insp</sub> and X<sub>rs,exp</sub> were easily detected during an exacerbation in subjects with COPD, were widely associated with changes in symptom and HRQOL scores and could represent useful objective measurements for documenting

recovery from an exacerbation. By contrast, changes in R<sub>rs,insp</sub> and R<sub>rs,exp</sub> were small in subjects with COPD and not useful in this context.

## ACKNOWLEDGEMENTS

This study was funded by the Scottish Executive.



Supplementary table E1 is available at <http://thorax.bmj.com/supplemental>

## Authors' affiliations

**Martin K Johnson**, Department of Respiratory Medicine, Gartnavel General Hospital, Glasgow, UK

**Malcolm Birch**, Department of Clinical Physics, Royal London Hospital, London, UK

**Roger Carter, Robin D Stevenson**, Department of Respiratory Medicine, Glasgow Royal Infirmary, Glasgow, UK

**John Kinsella**, University Department of Anaesthesia, Glasgow Royal Infirmary, Glasgow, UK

Competing interests: None.

## REFERENCES

- 1 **Seemungal TA**, Donaldson GC, Bhowmik A, *et al*. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2000;**161**:1608–13.
- 2 **Parker CM**, Voduc N, Aaron SD, *et al*. Physiological changes during symptom recovery from moderate exacerbations of COPD. *Eur Respir J* 2005;**26**:420–8.
- 3 **Skwarska E**, Cohen G, Skwarski KM, *et al*. Randomized controlled trial of supported discharge in patients with exacerbations of chronic obstructive pulmonary disease. *Thorax* 2000;**55**:907–12.
- 4 **Wood-Baker RR**, Gibson PG, Hannay M, *et al*. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*, 2005;CD001288.
- 5 **Niewoehner DE**, Collins D. Relation of FEV<sub>1</sub> to clinical outcomes during exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. *Am J Respir Crit Care Med* 2000;**161**:1201–5.
- 6 **Woolhouse IS**, Hill SL, Stockley RA. Symptom resolution assessed using a patient directed diary card during treatment of acute exacerbations of chronic bronchitis. *Thorax* 2001;**56**:947–53.
- 7 **Spencer S**, Jones PW, GLOBE Study Group. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. *Thorax* 2003;**58**:589–93.
- 8 **Doll H**, Miravittles M. Health-related QOL in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease: a review of the literature. *Pharmacoeconomics* 2005;**23**:345–63.
- 9 **Spencer S**, Calverley PM, Burge PS, *et al*. Impact of preventing exacerbations on deterioration of health status in COPD. *Eur Respir J* 2004;**23**:698–702.
- 10 **Oostveen E**, Macleod D, Lorino H, *et al*. The forced oscillation technique in clinical practice: methodology, recommendations and future developments. *Eur Respir J* 2003;**22**:1026–41.
- 11 **Johnson MK**, Birch M, Carter R, *et al*. Use of reactance to estimate transpulmonary resistance. *Eur Respir J* 2005;**25**:1061–9.
- 12 **Dellaca RL**, Santus P, Aliverti A, *et al*. Detection of expiratory flow limitation in COPD using the forced oscillation technique. *Eur Respir J* 2004;**23**:232–40.
- 13 **Dellaca RL**, Rotger M, Aliverti A, *et al*. Noninvasive detection of expiratory flow limitation in COPD patients during nasal CPAP. *Eur Respir J* 2006;**27**:983–91.
- 14 **Stevenson NJ**, Walker PP, Costello RW, *et al*. Lung mechanics and dyspnea during exacerbations of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2005;**172**:1510–16.
- 15 **BTS guidelines for the management of chronic obstructive pulmonary disease**. The COPD Guidelines Group of the Standards of Care Committee of the BTS, *Thorax*, 1997;**52**(Suppl 5):S1–28.
- 16 **Davies L**, Angus RM, Calverley PMA. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. *Lancet* 1999;**354**:456–60.
- 17 **Quanjer PHH**, Tammeling GJ, Cotes JE, *et al*. Lung volumes and forced ventilatory flows. *Eur Respir J* 1993;**6**(Suppl 16):5–40.
- 18 **Guidelines for the measurement of respiratory function**. Recommendations of the British Thoracic Society and the Association of Respiratory Technicians and Physiologists. *Respir Med* 1994;**88**:165–94.
- 19 **Pitkin AD**, Roberts CM, Wedzicha JA. Arterialised earlobe blood gas analysis: an underused technique. *Thorax* 1994;**49**:364–6.
- 20 **Horowitz JG**, Siegel SD, Primiano FP Jr, *et al*. Computation of respiratory impedance from forced sinusoidal oscillations during breathing. *Comput Biomed Res* 1983;**16**:499–521.

- 21 **Michaelson ED**, Grassman ED, Peters WR. Pulmonary mechanics by spectral analysis of forced random noise. *J Clin Invest* 1975;**56**:1210–30.
- 22 **Paggiaro PL**, Dahle R, Bakran I, et al. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. *Lancet* 1998;**351**:773–80.
- 23 **Borg GA**. Psychophysical bases of perceived exertion. *Med Sci Sports Exerc* 1982;**14**:377–81.
- 24 **McGavin CR**, Artvinli M, Naoe H, et al. Dyspnoea, disability, and distance walked: comparison of estimates of exercise performance in respiratory disease. *BMJ* 1978;**2**:241–3.
- 25 **Mahler DA**, Weinberg DH, Wells CK, et al. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. *Chest* 1984;**85**:751–8.
- 26 **Garrod R**, Bestall JC, Paul EA, et al. Development and validation of a standardized measure of activity of daily living in patients with severe COPD: the London Chest Activity of Daily Living scale (LCADL). *Respir Med* 2000;**94**:589–96.
- 27 **Jones PW**, Quirk FH, Baveystock CM, et al. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. *Am Rev Respir Dis* 1992;**145**:1321–7.
- 28 **Phagoo SB**, Watson RA, Silverman M, et al. Comparison of four methods of assessing airflow resistance before and after induced airway narrowing in normal subjects. *J Appl Physiol* 1995;**79**:518–25.
- 29 **Johnson MK**. *Non-invasive measurement of respiratory mechanics and mechanical work of breathing*, MD thesis, University of Glasgow, 2006.
- 30 **Cotes JE**, Chinn DJ, Miller MR. Determinants of maximal flows (flow limitation). In: *Lung function*. Oxford: Blackwell, 2006:143–9.
- 31 **O'Donnell DE**, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1999;**160**:542–9.